Xenon Pharmaceuticals (XENE) Enterprise Value (2016 - 2025)
Xenon Pharmaceuticals (XENE) has disclosed Enterprise Value for 13 consecutive years, with -$349.7 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 44.21% to -$349.7 million in Q4 2025 year-over-year; TTM through Sep 2025 was -$462.3 million, a 29.32% increase, with the full-year FY2025 number at -$349.7 million, up 44.21% from a year prior.
- Enterprise Value was -$349.7 million for Q4 2025 at Xenon Pharmaceuticals, up from -$462.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$249.6 million in Q3 2021 to a low of -$977.0 million in Q2 2025.
- A 5-year average of -$558.3 million and a median of -$550.7 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: plummeted 211.74% in 2021, then soared 44.21% in 2025.
- Xenon Pharmaceuticals' Enterprise Value stood at -$551.8 million in 2021, then fell by 7.31% to -$592.1 million in 2022, then dropped by 7.77% to -$638.1 million in 2023, then grew by 1.75% to -$626.9 million in 2024, then skyrocketed by 44.21% to -$349.7 million in 2025.
- Per Business Quant, the three most recent readings for XENE's Enterprise Value are -$349.7 million (Q4 2025), -$462.3 million (Q3 2025), and -$977.0 million (Q2 2025).